Related Experiment Videos
Pretreatment serum LDH as additional staging parameter in small-cell lung carcinoma
M P Stokkel1, B L van Eck-Smit, A H Zwinderman
1Department of Diagnostic Radiology and Nuclear Medicine, Leiden University Medical Centre, Netherlands.
The Netherlands Journal of Medicine
|April 29, 1998
Summary
Lactate dehydrogenase (LDH) levels can identify prognostic subgroups in limited stage small-cell lung cancer (SCLC). Patients with pretreatment LDH > 240 IU/l face high recurrence risk and poor survival, unlike those with lower levels.
Area of Science:
- Oncology
- Biochemistry
Background:
- Limited stage small-cell lung cancer (SCLC) has poor overall survival.
- Identifying prognostic subgroups at diagnosis is crucial for treatment stratification.
Purpose of the Study:
- To identify a prognostic parameter for limited stage SCLC.
- To correlate pretreatment biochemical markers with clinical outcomes.
Main Methods:
- Retrospective analysis of 48 limited stage SCLC patients.
- Clustering patients into complete remission, local recurrence, and distant recurrence groups.
- Correlation of age, gender, and pretreatment biochemical parameters with outcome and survival.
Main Results:
- Lactate dehydrogenase (LDH) was the sole significant correlate of tumor progression and survival.
- Patients with pretreatment LDH > 240 IU/l showed a high rate of tumor recurrence (100%) and poor survival (8% 2-year survival).
- Patients with pretreatment LDH < 240 IU/l had significantly better survival (41% 2-year survival).
Conclusions:
- LDH is a valuable biomarker for identifying prognostic subgroups in limited stage SCLC.
- Pretreatment LDH levels > 240 IU/l indicate an extremely high risk of recurrence and poor prognosis.
- Lower pretreatment LDH levels (< 240 IU/l) are associated with significantly better survival outcomes.